MedTrace Logo

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

NCT00835978 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2017-05-30

Study results available
· View outcomes & findings →

Summary

Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.

Conditions

  • Carcinoma, Renal Cell

Interventions

DRUG

axitinib

axitinib 5mg BID (open-label) + axitinib dose titration (blinded)

DRUG

axitinib

axitinib 5mg BID (open-label) + placebo dose titration (blinded)

DRUG

axitinib

axitinib 5mg BID (open-label)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2012-10-31
Completion
2016-02-29

Countries

  • United States
  • Czechia
  • Germany
  • Japan
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00835978 on ClinicalTrials.gov